Infinity Pharmaceuticals Inc. (NASDAQ: INFI) is 12.50% higher on its value in year-to-date trading and has touched a low of $0.60 and a high of $1.75 in the current 52-week trading range. The INFI stock was last observed hovering at around $1.08 in the recent trading session, with the current loss setting it -0.07% off its average median price target of $2.75 for the next 12 months. It is also 71.14% off the consensus price target high of $3.50 offered by 5 analysts, but current levels are -1.0% lower than the price target low of $1.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $1.01, the stock is 10.97% and 6.56% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.65 million and changing -6.02% at the moment leaves the stock -4.84% off its SMA200. INFI registered -36.09% loss for a year compared to 6-month loss of 0.93%. The firm has a 50-day simple moving average (SMA 50) of $0.9188 and a 200-day simple moving average (SMA200) of $1.0494.
The stock witnessed a 10.15% gain in the last 1 month and extending the period to 3 months gives it a 10.77%, and is 22.62% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.91% over the week and 7.79% over the month.
Infinity Pharmaceuticals Inc. (INFI) has around 25 employees, a market worth around $61.33M and $1.30M in sales. Distance from 52-week low is 69.17% and -42.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-592.30%).
Infinity Pharmaceuticals Inc. (INFI) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Infinity Pharmaceuticals Inc. (INFI) is a “Overweight”. 5 analysts offering their recommendations for the stock have an average rating of 2.50, where 1 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Infinity Pharmaceuticals Inc. is expected to release its quarterly report on 08/11/2020 and quarterly earnings per share for the current quarter are estimated at -$0.19 with sales reaching $160k over the same period.The EPS is expected to shrink by -306.60% this year, but quarterly earnings will post -37.40% year-over-year. Quarterly sales are estimated to shrink -37.70% in year-over-year returns.
Infinity Pharmaceuticals Inc. (INFI) Top Institutional Holders
60 institutions hold shares in Infinity Pharmaceuticals Inc. (INFI), with 2.02M shares held by insiders accounting for 3.51% while institutional investors hold 52.48% of the company’s shares. The shares outstanding are 57.34M, and float is at 55.35M with Short Float at 0.09%. Institutions hold 50.64% of the Float.
The top institutional shareholder in the company is BVF Inc. with over 17.43 million shares valued at $14.6 million. The investor’s holdings represent 30.34% of the INFI Shares outstanding. As of Mar 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 2.31 million shares valued at $1.94 million to account for 4.03% of the shares outstanding. The other top investors are Renaissance Technologies, LLC which holds 1.39 million shares representing 2.41% and valued at over $1.16 million, while Dimensional Fund Advisors LP holds 1.72% of the shares totaling 0.99 million with a market value of $0.83 million.
Infinity Pharmaceuticals Inc. (INFI) Insider Activity
A total of 1 insider transactions have happened at Infinity Pharmaceuticals Inc. (INFI) in the last six months, with sales accounting for 0 and purchases happening 1 times.
Infinity Pharmaceuticals Inc. (INFI): Who are the competitors?
The company’s main competitors (and peers) include AbbVie Inc. (ABBV) that is trading 36.69% up over the past 12 months. Bristol-Myers Squibb Company (BMY) is 26.44% up on the 1-year trading charts. Short interest in the company’s stock has risen 41.37% from the last report on May 14, 2020 to stand at a total of 28490.0 short shares sold with a short interest ratio of 0.22.